Bladder Dysfunction, Neurogenic Bladder Dysfunction, Urinary Incontinence, Urinary Bladder, Overactive, Urinary Incontinence, Urge, Nocturia, Urinary Frequency More Than Once at Night, Lower Urinary Tract Symptoms, Multiple Sclerosis, Urinary Bladder, Neurogenic
Conditions
Keywords
Multiple sclerosis, Neurogenic bladder, Feasibility study, Tibial nerve stimulation
Brief summary
Neurogenic lower urinary tract dysfunction is common among people with Multiple sclerosis with a pooled prevalence of 68.41% using self-report measures and 63.95% using urodynamic studies. Transcutaneous Tibial Nerve Stimulation (TTNS) is a non-invasive treatment option to manage bladder storage symptoms, however, the potential efficacy of TTNS among people with multiple sclerosis is based on a small number of studies with the absence of high-quality evidence relating to efficacy, and lack of clarity of the optimal electrical stimulation parameters and frequency, duration and number of treatment sessions. The feasibility and acceptability of TTNS to manage storage bladder symptoms using Transcutaneous Electrical Nerve Stimulation (TENS) needs to be established before proceeding with a definitive randomised trial. This study aims to assess whether TTNS is feasible and acceptable as a treatment for bladder storage symptoms in people with MS
Detailed description
The investigators will use a single-arm experimental study to explore the feasibility and acceptability of TTNS in the treatment of bladder storage symptoms in multiple sclerosis. The CONSORT extension for pilot and feasibility studies will be followed to standardise the conduct and reporting of the study. The recruitment plan is twofold: 1) Open recruitment for people with MS through MS Ireland's communication channels; 2) Recruitment from a convenience sample of people with MS who have previously participated in a qualitative study. The investigators will assess recruitment/retention rates, the urinary symptoms changes and the effect on quality of life using International classification of incontinence questionnaire - overactive bladder (ICIQ-OAB), 3-day bladder diary, King's Health Questionnaire and collect self-reported data on adherence and adverse events and acceptability of using TTNS.
Interventions
Transcutaneous tibial nerve stimulation is a non-invasive electrical stimulation of the posterior tibial nerve, a branch of the sciatic nerve via sacral plexus. In our study the tibial nerve will be stimulated using Transcutaneous Electrical Nerve Stimulation (TENS) unit with two surface adhesive electrodes. The anode will be positioned between 5-10 cm above medial malleolus and posterior to the edge of the tibia and the cathode will be positioned distally on arch of the foot .
Sponsors
University of Limerick
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
Single-arm feasibility study
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Self-reported diagnosis of any type of Multiple Sclerosis * Male or female * Aged ≥18 years old * Ambulatory * At least one bladder storage related symptom (e.g. urinary frequency, urinary urgency, nocturia with or without incontinence).
Exclusion criteria
* People with an indwelling urethral catheter or indwelling suprapubic catheter * Urologic disease including bladder malignancy * Diabetic mellitus * Pregnant women or planning to be pregnant during the study time * Recent pelvic related surgery \<1 year * Pacemaker or other metallic internal devices * Urinary tract infections (UTIs) during recruitment phase.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Acceptability of using TTNS: proportion of participants with MS reporting that TTNS is acceptable | 6 weeks | The proportion of participants with MS reporting that TTNS is acceptable. |
| Recruitment rate/ retention rate | 6 weeks | The proportion of participants who are recruited to the study and the proportion of participants who are lost to follow up |
| Adherence rate | 6 weeks | The proportion of participants who adhere to the treatment protocol of 6 weeks |
| Adverse events | 6 weeks | Number of participants with adverse events as a measure of safety |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| International Consultation of Incontinence Questionnaire-Overactive bladder (ICIQ-OAB) | 6 weeks | Changes in the severity of scores for bladder storage symptoms experienced by participants measured using ICIQ-OAB. It has grade A for validity, reliability and responsiveness to change established with rigour on one data set. The total score ranges from 0 to 16 with higher values indicating increased symptom severity. Bother scales are not incorporated in the overall score. |
| Kings Health Questionnaire | 6 weeks | Changes in scores for the effect of urinary symptoms in activity of daily living measured by the Kings Health Questionnaire. Each domain within the Kings Health Questionnaire is scored on a 0 (best) to 100 (worst) scale. A change from baseline of 5 points or higher on most of the King's Health Questionnaire domains represents a clinically meaningful improvement in health-related quality of life after treatment. |
| 3- day bladder diary | 6 weeks | Number of episodes of frequency, nocturia, and incontinence/ 72 hours will be calculated and compared from baseline with higher values indicating increased symptom severity. |
| Patient Perception of Intensity of Urgency Scale | 6 weeks | Number of urgency episodes and severity of urgency/72 hours will be calculated and compared from baseline. The total score ranges from 0 to 4 with higher values indicating increased symptom severity. |
Countries
Ireland
Outcome results
None listed